Encorafenib and Binimetinib

descriptionPublicationkeyboard_double_arrow_right Part of book or chapter of book , Other literature type 01 Jan 2021 English Publisher:Springer International Publishing

Authors: Iwona Lugowska; Paweł Rogala;

doi: 10.1007/978-3-030-64009-5_7

Encorafenib and Binimetinib

- Summary
- Metrics

Abstract

The BRAF/MEK inhibitors, encorafenib and binimetinib, is the FDA/EMA-approved combination used in BRAF-positive melanoma. The phase III study showed an improvement in progression-free survival (PFS) and overall survival (OS) with good tolerability. A direct comparison of monotherapy showed better results in the arm with encorafenib over vemurafenib. This review provides an overview of pharmacological properties, efficacy, and toxicity of encorafenib and binimetinib.

Related Organizations

Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology
Poland

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	0
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average